A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease

Journal of Gastroenterology

Volumn 52, Issue 11, 2017, Pages 1201-1210

  Kim, Tae Jun ^a   Sinn, Dong Hyun ^a   Min, Yang Won ^a   Son, Hee Jung ^a   Kim, Jae J ^a   Chang, Yoosoo ^b,c   Baek, Sun Young ^a   Ahn, Soo Hyun ^a   Lee, Hyuk ^a   Ryu, Seungho ^b,c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

Cohort study; Helicobacter pylori; Incidence; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G ANTIBODY; INSULIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASYMPTOMATIC DISEASE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; DYSLIPIDEMIA; ECHOGRAPHY; EDUCATIONAL STATUS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FATTY LIVER INDEX; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATOBILIARY PARAMETERS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HYPERTENSION; INCIDENCE; INDEPENDENT VARIABLE; INFLAMMATION; INSULIN BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; METABOLIC DISORDER; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REPEAT PROCEDURE; RETROSPECTIVE STUDY; RISK FACTOR; SEX; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; COMPLICATION; DIAGNOSTIC IMAGING; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIVARIATE ANALYSIS; PROCEDURES;

ADULT; BODY MASS INDEX; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LONGITUDINAL STUDIES; MALE; MASS SCREENING; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDIES; RISK FACTORS; ULTRASONOGRAPHY;

EID: 85017105642     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-017-1337-y     Document Type: Article

References (50)

1. Everhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am. 2000;29:559–78.
2. Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology. 2006;130:188–206.
3. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175–86.
4. Goni E, Franceschi F. Helicobacter pylori and extragastric diseases. Helicobacter. 2016;21(Suppl 1):45–8.
5. Park MJ, Choi SH, Kim D, et al. Association between Helicobacter pylori seropositivity and the coronary artery calcium score in a screening population. Gut Liver. 2011;5:321–7.
6. Jamali R, Mofid A, Vahedi H, et al. The effect of Helicobacter pylori eradication on liver fat content in subjects with non-alcoholic fatty liver disease: a randomized open-label clinical trial. Hepat Mon. 2013;13:e14679.
7. Hsieh MC, Wang SS, Hsieh YT, et al. Helicobacter pylori infection associated with high HbA1c and type 2 diabetes. Eur J Clin Invest. 2013;43:949–56.
8. Satoh H, Saijo Y, Yoshioka E, et al. Helicobacter pylori infection is a significant risk for modified lipid profile in Japanese male subjects. J Atheroscler Thromb. 2010;17:1041–8.
9. Gunji T, Matsuhashi N, Sato H, et al. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gastroenterol. 2008;103:3005–10.
10. Korean Association for the Study of the L. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2013;19:325–48.
11. Adams LA, Waters OR, Knuiman MW, et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104:861–7.
12. Lonardo A, Loria P. NAFLD and cardiovascular risk: direct evidence for the tale of two ages. Am J Gastroenterol. 2009;104:1851–2.
13. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
14. Sookoian S, Pirola CJ. Nonalcoholic fatty liver disease and metabolic syndrome: shared genetic basis of pathogenesis. Hepatology. 2016;64:1417–20.
15. Li M, Shen Z, Li YM. Potential role of Helicobacter pylori infection in nonalcoholic fatty liver disease. World J Gastroenterol. 2013;19:7024–31.
16. Polyzos SA, Kountouras J, Zavos C, et al. Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease. Med Hypotheses. 2014;82:795.
17. Sumida Y, Kanemasa K, Imai S, et al. Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease. J Gastroenterol. 2015;50:996–1004.
18. Baeg MK, Yoon SK, Ko SH, et al. Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease. World J Gastroenterol. 2016;22:2592–600.
19. Polyzos SA, Kountouras J, Papatheodorou A, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism. 2013;62:121–6.
20. Takuma Y. Helicobacter pylori infection and liver diseases. Gan To Kagaku Ryoho. 2011;38:362–4.
21. Okushin K, Takahashi Y, Yamamichi N, et al. Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. BMC Gastroenterol. 2015;15:25.
22. Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587.
23. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed). 1986;292:13–5.
24. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
25. Global Burden of Metabolic Risk Factors for Chronic Diseases C, Lu Y, Hajifathalian K, Ezzati M, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet. 2014;383:970–83.
26. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med. 1997;16:1515–27.
27. Hafeman DM. ”Proportion explained”: a causal interpretation for standard measures of indirect effect? Am J Epidemiol. 2009;170:1443–8.
28. Kim JH, Kwon SY, Lee SW, et al. Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population. Liver Int. 2011;31:1600–1.
29. Meffert PJ, Baumeister SE, Lerch MM, et al. Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis. Am J Gastroenterol. 2014;109:1404–14.
30. Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
31. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut. 1994;35:742–5.
32. Moayyedi P, Axon AT, Feltbower R, et al. Relation of adult lifestyle and socioeconomic factors to the prevalence of Helicobacter pylori infection. Int J Epidemiol. 2002;31:624–31.
33. Park MJ, Yun KE, Lee GE, et al. A cross-sectional study of socioeconomic status and the metabolic syndrome in Korean adults. Ann Epidemiol. 2007;17:320–6.
34. Jia G, Li X, Wang L, et al. Relationship of socioeconomic status and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Zhonghua Gan Zang Bing Za Zhi. 2015;23:760–4.
35. Polyzos SA, Kountouras J, Zavos C, et al. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter. 2011;16:79–88.
36. Peach HG, Barnett NE. Helicobacter pylori infection and fasting plasma glucose concentration. J Clin Pathol. 2001;54:466–9.
37. Gillum RF. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the third national health and nutrition examination survey. J Natl Med Assoc. 2004;96:1470–6.
38. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–9.
39. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46:1081–90.
40. Kim TJ, Lee H, Kang M, et al. Helicobacter pylori is associated with dyslipidemia but not with other risk factors of cardiovascular disease. Sci Rep. 2016;6:38015.
41. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877–87.
42. Korponay-Szabo IR, Halttunen T, Szalai Z, et al. In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut. 2004;53:641–8.
43. Sandler NG, Koh C, Roque A, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology. 2011;141:1220–30.
44. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082–90.
45. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology. 2003;124:248–50.
46. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988–1994. Am J Epidemiol. 2013;178:38–45.
47. Lim SH, Kwon JW, Kim N, et al. Prevalence and risk factors of Helicobacter pylori infection in Korea: nationwide multicenter study over 13 years. BMC Gastroenterol. 2013;13:104.
48. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter. 2007;12:333–40.
49. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean J Gastroenterol. 2013;62:3–26.
50. Kim N, Kim JJ, Choe YH, et al. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2009;54:269–78.